4 results about "Nojirimycin" patented technology

The invention belongs to the technical field of biology, and discloses a transaminase GabT1 mutant S106I, a construction method thereof and application of the transaminase GabT1 mutant S106I in biosynthesis of 1-deoxynojirimycin. According to the invention, the 106th serine near the molecular catalytic domain of the transaminase GabT1 derived from bacillus amyloliquefaciens is mutated into isoleucine in a site-directed mutagenesis manner, so that the catalytic efficiency of the transaminase GabT1 is remarkably improved, the problem that the catalytic efficiency of the transaminase GabT1 on fructose-6-phosphoric acid is not high at present is solved, and the application of the transaminase GabT1 to the fructose-6-phosphoric acid is promoted. The yield of 1-deoxynojirimycin synthesized by the mutant GabTS106I is increased by 43.87% compared with that of a wild type. The 1-deoxynojirimycin fermentation production capability of the transaminase GabT1 mutant and the engineering strain obtained by the invention is greatly improved, and the transaminase GabT1 mutant and the engineering strain have a good industrial application prospect.

The application provides an amphiphilic nobeliatin molecule, a preparation method thereof and a blood glucose lowering and antibacterial application to a diabetic wound. The application relates to the technical field of biomedical materials. The application synthesizes a novel amphiphilic nobeliatin molecule by taking 1-deoxynobeliatin as a hydrophilic part and an alkyl chain as a hydrophobic part. The compound can self-assemble into a cluster sugar molecule in an aqueous solution, has good blood glucose lowering activity through the "multivalent effect" of the cluster sugar-glycosidase, has good antibacterial activity through the tertiary amine structure of the azasugar molecule and the long alkyl chain and the bacterial membrane, and realizes the compatibility of the blood glucose lowering effect and the antibacterial effect. The synthesis raw material of the nobeliatin molecule provided by the application is rich in source, low in price, simple in preparation process and convenient for industrial application. Therefore, the discovery of the compound is expected to provide a promising treatment scheme for the development of blood glucose lowering and antibacterial integrated materials and the treatment of diabetic wounds, and has a wide potential application field.

Disclosed are a 1-deoxynojirimycin derivative and use thereof. According to the present invention, a variety of 1-deoxynojirimycin derivatives are prepared and obtained through screening. Compared with 1-deoxynojirimycin as a lead compound, the 1-deoxynojirimycin derivative can better bind to an amino acid site that is related to a target protein OPA1, stabilize a binding pocket at a dimer interface, promote the formation of an OPA1 dimer and repair a mitochondrial ultrastructure, thereby significantly saving mitochondrial functions and effectively improving a physiological state of cells. The 1-deoxynojirimycin derivative of the present invention can be used for preparing a drug for treating a disease that is related to unbalanced formation of the OPA1 dimer, and for example, can be used as a potential therapeutic drug for mitochondrial cardiomyopathy and other mitochondrial diseases.

The present invention discloses 1-deoxynojirimycin derivatives and their uses. Through screening, several 1-deoxynojirimycin derivatives were prepared. Compared with the lead compound 1-deoxynojirimycin, these derivatives better bind to the relevant amino acid site of the target protein OPA1 and are stabilized in the binding pocket of the dimer interface. They promote the formation of OPA1 dimers and restore mitochondrial ultrastructure, thereby significantly maintaining mitochondrial function and effectively improving cellular physiological status. The 1-deoxynojirimycin derivatives of the present invention are useful for preparing drugs for treating diseases associated with an imbalance in OPA1 dimer formation, and are promising therapeutic agents for, for example, mitochondrial cardiomyopathy and other mitochondrial diseases.